Clinical Trial Update: An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions [Phase 1]

View source ↗

Summary

An open-label Phase 1 study in healthy participants to assess whether AZD0780 acts as a perpetrator or victim of CYP3A4-mediated drug-drug interactions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• AZD0780

Snippet

Sponsor: AstraZeneca | Conditions: Dyslipidaemia | Phase 1 | Status: COMPLETED